Fintel reports that on August 10, 2023, Cantor Fitzgerald reiterated coverage of Denali Therapeutics (NASDAQ:DNLI) with a Overweight recommendation.
Analyst Price Forecast Suggests 143.05% Upside
As of August 2, 2023, the average one-year price target for Denali Therapeutics is 60.11. The forecasts range from a low of 30.30 to a high of $110.25. The average price target represents an increase of 143.05% from its latest reported closing price of 24.73.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Denali Therapeutics is 89MM, a decrease of 74.07%. The projected annual non-GAAP EPS is -3.14.
What is the Fund Sentiment?
There are 447 funds or institutions reporting positions in Denali Therapeutics. This is an increase of 5 owner(s) or 1.13% in the last quarter. Average portfolio weight of all funds dedicated to DNLI is 0.21%, a decrease of 27.96%. Total shares owned by institutions increased in the last three months by 0.05% to 114,150K shares. 
The put/call ratio of DNLI is 0.25, indicating a bullish outlook.
What are Other Shareholders Doing?
Baillie Gifford holds 14,844K shares representing 10.84% ownership of the company. In it's prior filing, the firm reported owning 15,352K shares, representing a decrease of 3.42%. The firm decreased its portfolio allocation in DNLI by 55.87% over the last quarter.
Temasek Holdings holds 6,896K shares representing 5.04% ownership of the company. In it's prior filing, the firm reported owning 6,516K shares, representing an increase of 5.51%. The firm decreased its portfolio allocation in DNLI by 10.98% over the last quarter.
Crestline Management holds 6,411K shares representing 4.68% ownership of the company. In it's prior filing, the firm reported owning 6,861K shares, representing a decrease of 7.02%. The firm decreased its portfolio allocation in DNLI by 37.27% over the last quarter.
Wellington Management Group Llp holds 5,200K shares representing 3.80% ownership of the company. In it's prior filing, the firm reported owning 5,122K shares, representing an increase of 1.51%. The firm decreased its portfolio allocation in DNLI by 88.27% over the last quarter.
VGHCX - Vanguard Health Care Fund Investor Shares holds 4,921K shares representing 3.59% ownership of the company. In it's prior filing, the firm reported owning 3,057K shares, representing an increase of 37.88%. The firm increased its portfolio allocation in DNLI by 29.65% over the last quarter.
Denali Therapeutics Background Information
(This description is provided by the company.)
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.
Additional reading:
- Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
- Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
- Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
- Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Amendment No. 7 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated March 29, 2021.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
